Cardiovascular risk factors affecting COVID-19 outcomes at a tertiary referral hospital in northwest Iran: A prospective cohort study

Abstract

Objective: To investigate cardiovascular risk factors affecting COVID-19 outcomes in a tertiary referral hospital. Methods: This prospective cohort study analyzed 269 participants with COVID-19. The primary outcomes were ICU admission, prolonged hospital stay duration, and in-hospital death. The secondary outcomes included death, chronic symptoms, and NYHA functional class during follow-up periods. Results: A total of 412 patients with COVID-19 symptoms were enrolled in the study, and out of which 269 patients had complete medical records and positive SARS-CoV-2 PCR test results, fulfilling the study criteria were analyzed. The patients were divided into two groups, with cardiovascular comorbidities (group A, n=122), such as established cardiovascular disease, diabetes mellitus, and hypertension, and without cardiovascular comorbidities (group B, n=147). Binary logistic regression analysis showed that patients with underlying hypertension, diabetes, and established cardiovascular disease had a 1.55 (95% CI: 1.28-2.26), 1.62 (95% CI: 1.34-2.13), and 1.63 (95% CI: 1.07-5.34)-fold risk of mortality, respectively in the adjusted model. Conclusions: Hospitalized COVID-19 patients with predisposing cardiovascular risk factors are more susceptible to develop worse outcomes. More attention should be paid to the management and follow-up of these patients.

Keywords

COVID-19 / Outcome / Cardiovascular / Chronic symptoms / Diabetes mellitus / Hypertension

References

[1] Cucinotta D, Vanelli M. WHO declares COVID—19 a pandemic. Acta Biomed 2020; 91(1): 157-160.

[2] Miller M. 2019 Novel coronavirus COVID—19 (2019—nCoV) data repository: Johns Hopkins University Center for Systems Science and Engineering. ACMLA 2020; 164: 47-51.

[3] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727-733.

[4] Jegan R, Rajalakshmy P, Subha Hency Jose P, Nimi WS. 2019—nCoV effects, transmission and preventive measures: An overview. Z Gesundh Wiss 2023; 31(1): 27-35.

[5] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395(10223): 507-513.

[6] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.

[7] Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID—19). JAMA Cardiol 2020; 5(7): 811-818.

[8] Wei JF, Huang FY, Xiong TY, Liu Q, Chen H, Wang H, et al. Acute myocardial injury is common in patients with COVID—19 and impairs their prognosis. Heart 2020; 106(15): 1154-1159.

[9] Inciardi RM, Adamo M, Lupi L, Cani DS, Di Pasquale M, Tomasoni D, et al. Characteristics and outcomes of patients hospitalized for COVID—19 and cardiac disease in Northern Italy. Eur Heart J 2020; 41(19): 1821-1829.

[10] Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID—19 in a multistate health care systems network—United States, March—June 2020. MMWR Morb Mortal Wkly Rep 2020; 69(30): 993-998.

[11] The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID—19)—China, 2020. China CDC Wkly 2020; 2(8): 113-122.

[12] Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020; 133(9): 1025-1031.

[13] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus—infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-1069.

[14] Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS—CoV—2 in Wuhan, China. Allergy 2020; 75(7): 1730-1741.

[15] Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical characteristics of imported cases of coronavirus disease 2019 (COVID—19) in Jiangsu Province: A multicenter descriptive study. Clin Infect Dis 2020; 71(15): 706-712.

[16] Ji D, Zhang D, Chen Z, Xu Z, Zhao P, Zhang M, et al. Clinical characteristics predicting progression of COVID—19. SSRN Electronic Journal 2020; DOI: 10.2139/ssrn.3539674. [Preprint].

[17] Corazza GR, Formagnana P, Lenti MV. Bringing complexity into clinical practice: An internistic approach. Eur J Intern Med 2019; 61: 9-14.

[18] Chacko B, Peter JV, Pichamuthu K, Ramakrishna K, Moorthy M, Karthik R, et al. Cardiac manifestations in patients with pandemic (H1N1) 2009 virus infection needing intensive care. J Crit Care 2012; 27(1): 106.e1-106.e6.

[19] Sabatino J, De Rosa S, Di Salvo G, Indolfi C. Impact of cardiovascular risk profile on COVID—19 outcome. A meta—analysis. PloS One 2020; 15(8): e0237131.

[20] Bae S, Kim SR, Kim MN, Shim WJ, Park SM. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID—19 according to age: A systematic review and meta—analysis. Heart 2021; 107(5): 373-380.

[21] Li X, Guan B, Su T, Liu W, Chen M, Bin Waleed K, et al. Impact of cardiovascular disease and cardiac injury on in—hospital mortality in patients with COVID—19: A systematic review and meta—analysis. Heart 2020; 106(15): 1142-1147.

[22] Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1 590 patients with COVID—19 in China: A nationwide analysis. Eur Respir J 2020; 55(5): 2000547.

[23] Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1 591 patients infected with SARS—CoV—2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020; 323(16): 1574-1581.

[24] Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ 2020; 368: m1091.

[25] Huang S, Wang J, Liu F, Liu J, Cao G, Yang C, et al. COVID—19 patients with hypertension have more severe disease: A multicenter retrospective observational study. Hypertens Res 2020; 43(8): 824-831.

[26] Dhaun N, Webb DJ. Endothelins in cardiovascular biology and therapeutics. Nat Rev Cardiol 2019; 16(8): 491-502.

[27] Zhang Y, Murugesan P, Huang K, Cai H. NADPH oxidases and oxidase crosstalk in cardiovascular diseases: Novel therapeutic targets. Nat Rev Cardiol 2020; 17(3): 170-194.

[28] Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID—19 and pre—existing type 2 diabetes. Cell Metab 2020; 31(6): 1068-1077. e3.

[29] Silverio A, Di Maio M, Citro R, Esposito L, Iuliano G, Bellino M, et al. Cardiovascular risk factors and mortality in hospitalized patients with COVID—19: Systematic review and meta—analysis of 45 studies and 18 300 patients. BMC Cardiovasc Disord 2021; 21(1): 23.

[30] Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Esposito K. Glycemic control, preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: Systematic review with meta—analysis of cardiovascular outcome trials and intensive glucose control trials. J Am Heart Assoc 2019; 8(12): e012356.

[31] Wu J, Zhang Y, Li J, Lin S, Wang L, Jiang Y, et al. Increase in nontuberculous mycobacteria isolated in Shanghai, China: Results from a population—based study. PLoS One 2014; 9(10): e109736.